Bartel S, Stein B, Eschenhagen T, Mende U, Neumann J, Schmitz W, Krause E G, Karczewski P, Scholz H
Max-Delbrück-Zentrum für Molekulare Medizin, Forschungsschwerpunkt Kardiologie, Berlin, Germany.
Mol Cell Biochem. 1996;157(1-2):171-9. doi: 10.1007/BF00227896.
Disturbances in the cAMP production during beta-adrenergic stimulation and alterations of Ca2+ transport controlling proteins and their regulation in the sarcoplasmic reticulum might be involved in the pathogenesis of the failing human heart. Thus, we investigated the cAMP-mediated phosphorylation of phospholamban, troponin I and C-protein in electrically driven, intact isolated trabeculae carneae from nonfailing and failing (NYHA IV) human hearts in parallel to contractile properties on the same tissue samples. The increase in force of contraction induced by isoproterenol (0.2 microM) or pimobendan (100 microM), a phosphodiesterase inhibitor, was diminished in the failing human hearts compared to nonfailing hearts by 49% and 36%, respectively. Concomitantly the isoproterenol-induced phosphorylation (pmol P/mg homogenate protein) of phospholamban, troponin I and C-protein was reduced from 13.0 +/- 2.4 (n = 4), 30.5 +/- 1.5 (n = 5) and 11.0 +/- 1.3 (n = 5) in the nonfailing heart to 5.2 +/- 0.6 (n = 13), 14.6 +/- 2.2 (n = 16) and 7.1 +/- 1.0 (n = 6) in the failing human heart, respectively. Pimobendan changed the phosphorylation state of these proteins similar to isoproterenol. The fact that combined addition of both agents or dibuturyl cAMP (1 mM) alone restored the phosphorylation capacity as observed in the control groups indicates that i) a reduced cAMP generation is related to the reduced phosphorylation of regulatory phosphoproteins located in the sarcoplasmic reticulum and contractile apparatus e.g. phospholamban, troponin I and C-protein, that ii) there is a relationship between protein phosphorylation state and contractile activity and that iii) no changes in the respective content of phosphoproteins are involved in the limitation of cAMP-mediated inotopic activity in the failing human heart.
β-肾上腺素能刺激过程中cAMP生成的紊乱以及肌浆网中Ca2+转运控制蛋白的改变及其调节可能与人类心力衰竭的发病机制有关。因此,我们研究了非衰竭和衰竭(纽约心脏协会IV级)人类心脏的电驱动完整分离心肌小梁中受磷蛋白、肌钙蛋白I和C蛋白的cAMP介导的磷酸化,并同时研究了相同组织样本的收缩特性。与非衰竭心脏相比,异丙肾上腺素(0.2微摩尔)或磷酸二酯酶抑制剂匹莫苯丹(100微摩尔)诱导的衰竭人类心脏收缩力增加分别降低了49%和36%。同时,异丙肾上腺素诱导的受磷蛋白、肌钙蛋白I和C蛋白的磷酸化(皮摩尔磷/毫克匀浆蛋白)在非衰竭心脏中分别为13.0±2.4(n = 4)、30.5±1.5(n = 5)和11.0±1.3(n = 5),而在衰竭人类心脏中分别降至5.2±0.6(n = 13)、14.6±2.2(n = 16)和7.1±1.0(n = 6)。匹莫苯丹改变这些蛋白的磷酸化状态与异丙肾上腺素相似。两种药物联合添加或单独添加二丁酰cAMP(1毫摩尔)可恢复对照组中观察到的磷酸化能力,这一事实表明:i)cAMP生成减少与位于肌浆网和收缩装置中的调节磷蛋白(如受磷蛋白、肌钙蛋白I和C蛋白)磷酸化减少有关;ii)蛋白磷酸化状态与收缩活性之间存在关系;iii)衰竭人类心脏中cAMP介导的变力活性受限与磷蛋白各自含量的变化无关。